Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
2016 2017 2018 2019 Billable/Specific Code T45.1X5A is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Short description: Adverse effect of antineoplastic and immunosup drugs, init The 2018/2019 edition of ICD-10-CM T45.1X5A became effective on October 1, 2018.
Complications of Cancer Treatment ICD-10-CM Code ICD-10-CM Description D61.1 Drug -induced aplastic anemia (aplastic ... D61.810 Antineoplastic chemotherapy induced panc ... D64.81 Anemia due to antineoplastic chemotherap ... D70.1 Agranulocytosis secondary to cancer chem ... 19 more rows ...
T45.1X5A is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Short description: Adverse effect of antineoplastic and immunosup drugs, init. The 2019 edition of ICD-10-CM T45.1X5A became effective on October 1, 2018.
Malignant neoplasm without specification of site Code C80.1, Malignant (primary) neoplasm, unspecified, equates to Cancer, unspecified. This code should only be used when no determination can be made as to the primary site of a malignancy. This code should rarely be used in the inpatient setting.
ICD-10 code D84. 9 for Immunodeficiency, unspecified is a medical classification as listed by WHO under the range - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism .
Z92. 25 - Personal history of immunosuppression therapy. ICD-10-CM.
ICD-10-CM Code for Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter T45. 1X5A.
ICD-10 code Z51. 11 for Encounter for antineoplastic chemotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
People with immunodeficiency or autoimmune disease are considered immunocompromised, but other factors can also cause someone to be immunocompromised, such as cancer, cancer treatments, metabolic disorders or advanced age, according to The University of Texas MD Anderson Cancer Center.
(IH-myoo-noh-suh-PREST) Having a weakened immune system. People who are immunosuppressed have a reduced ability to fight infections and other diseases. This may be caused by certain diseases or conditions, such as AIDS, cancer, diabetes, malnutrition, and certain genetic disorders.
1X5 for Adverse effect of antineoplastic and immunosuppressive drugs is a medical classification as listed by WHO under the range - Injury, poisoning and certain other consequences of external causes .
Cytotoxic chemotherapy for the treatment of cancer causes a range of side effects that adversely affect patient health and quality of life. One such side effect is myelosuppression, where chemotherapy massively depletes bone marrow progenitor cells resulting in anemia, neutropenia, and thrombocytopenia (1–3).
810 for Antineoplastic chemotherapy induced pancytopenia is a medical classification as listed by WHO under the range - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism .
Code 96413 (chemotherapy administration, intravenous infusion technique; up to one hour, single or initial substance/drug) would be used to report the first 90 minutes of the infusion.
ICD-10 Code for Other long term (current) drug therapy- Z79. 899- Codify by AAPC.
ICD-10 Code for Encounter for antineoplastic chemotherapy and immunotherapy- Z51. 1- Codify by AAPC. Factors influencing health status and contact with health services. Encounters for other specific health care. Encounter for other aftercare and medical care(Z51)
When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy at that site, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Any mention of extension, invasion, or metastasis to another site is coded as a secondary malignant neoplasm to that site. The secondary site may be the principal or first-listed with the Z85 code used as a secondary code.
There are also codes Z85.6, Personal history of leukemia, and Z85.79, Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues. If the documentation is unclear as to whether the leukemia has achieved remission, the provider should be queried.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion '), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous such as tumors in different quadrants of the same breast, codes for each site should be assigned.
Chapter 2 of the ICD-10-CM contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms , such as prostatic adenomas, may be found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant, or of uncertain histologic behavior. If malignant, any secondary ( metastatic) sites should also be determined.
Code C80.0, Disseminated malignant neoplasm, unspecified, is for use only in those cases where the patient has advanced metastatic disease and no known primary or secondary sites are specified. It should not be used in place of assigning codes for the primary site and all known secondary sites.
When a pregnant woman has a malignant neoplasm, a code from subcategory O9A.1 -, malignant neoplasm complicating pregnancy, childbirth, and the puerperium, should be sequenced first, followed by the appropriate code from Chapter 2 to indicate the type of neoplasm. Encounter for complication associated with a neoplasm.
When an encounter is for a pathological fracture due to a neoplasm, and the focus of treatment is the fracture, a code from subcategory M84.5, Pathological fracture in neoplastic disease, should be sequenced first, followed by the code for the neoplasm.
New codes were created in October 2020 to report specific causes for a patient’s immunocompromised state. Previously, there was no way to capture a patient who was immunocompromised or immunodeficient. The only way was to use the “long-term use of drugs” and/or the conditions related to the immunocompromised state.
Created for an immunocompromised state due to a specific medical condition such as HIV, AIDS *, ( See explanation below) certain cancers and genetic disorders that are classified elsewhere in ICD-10-CM.
Sequence either code J20.8, Acute bronchitis due to other specified organisms, or code H66.92, Otitis media, unspecified, left ear, as the first-listed diagnosis. Assign codes D84.821, Immunodeficiency due to drugs, for the patient’s immunosuppressed state as a result of chemotherapy, and T45.1X5A, Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter. In this case, immune suppression is not part of the intended effect of the antineoplastic drugs and is coded as an adverse effect. Additionally, assign codes C90.00, Multiple myeloma not having achieved remission, for the multiple myeloma and Z79.899, Other long term (current) drug therapy, for the chemotherapy.
When the immune system fails to respond adequately to infection, it’s called an immunodeficiency , and the patient may become immunocompromised.
Assign code L03.011, Cellulitis of the right finger, as the principal diagnosis. Assign codes M32.9, Systemic lupus erythematosus, unspecified, for SLE, D84.821, Immunodeficiency due to drugs, and Z79.899, Other long-term (current) drug therapy, for the patient’s immunosuppressed state due to long-term use of immunosuppressants.
*There was an update in the First Quarter 2021 Coding Clinic that clarified the use of D84.81. “It is not appropriate to assign code D84.81 , Immunodeficiency due to conditions classified elsewhere, together with code B20, human immunodeficiency virus (HIV) disease. Immunocompromise/immunodeficiency is part of the clinical picture in HIV disease, and code B20 captures fully the immunocompromised state .” Fortunately, there is an Excludes1 note under code D84.81, excluding B20, confirming that HIV/AIDS is not coded here.